Fluocinolone acetonide for the treatment of uveitis: Weighing the balance between local and systemic immunosuppression

Archives of Ophthalmology

Volumn 126, Issue 9, 2008, Pages 1287-1289

  Yeh, Steven ^b   Nussenblatt, Robert B ^a  

^a NATIONAL EYE INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTIMETABOLITE; CALCINEURIN INHIBITOR; CORTICOSTEROID; FLUOCINOLONE ACETONIDE;

CATARACT EXTRACTION; DRUG DELIVERY SYSTEM; EDITORIAL; IMMUNOSUPPRESSIVE TREATMENT; IMPLANTATION; PRIORITY JOURNAL; RECURRENT DISEASE; RETINA MACULA CYSTOID EDEMA; UVEITIS; VISUAL ACUITY;

DRUG IMPLANTS; FLUOCINOLONE ACETONIDE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSION; RECURRENCE; UVEITIS, POSTERIOR;

EID: 51649126810     PISSN: 00039950     EISSN: 00039950     Source Type: Journal    
DOI: 10.1001/archopht.126.9.1287     Document Type: Editorial

References (20)

1. Callanan DG, Jaffe GJ, Martin DF, Pearson PA, Comstock TL. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol. 2008;126(9):1191-1201.
2. Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology. 2006;113(6):1020-1027.
3. Goldstein DA, Godfrey DG, Hall A, et al. Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants. Arch Ophthalmol. 2007;125(11):1478-1485.
4. Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108(11):1943- 1953.
5. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130(4):492-513.
6. Read RW. Uveitis: advances in understanding of pathogenesis and treatment. Curr Rheumatol Rep. 2006;8(4):260-266.
7. Jabs DA, Akpek EK. Immunosuppression for posterior uveitis. Retina. 2005;25(1):1-18.
8. Yeh S, Faia LJ, Nussenblatt RB. Advances in the diagnosis and immunotherapy for ocular inflammatory disease. Semin Immunopathol. 2008;30(2):145-164.
9. Kempen JH, Daniel E, Gangaputra S, et al. Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. Ophthalmic Epidemiol. 2008;15(1):47-55.
10. Nussenblatt RB, Palestine AG, Chan CC, Stevens G Jr, Mellow SD, Green SB. Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. Am J Ophthalmol. 1991;112(2):138-146.
11. Nussenblatt RB, Fortin E, Schiffman R, et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci U S A. 1999;96(13):7462-7466.
12. Chan CC, Li Q. Immunopathology of uveitis. Br J Ophthalmol. 1998;82(1):91-96.
13. Kok H, Lau C, Maycock N, McCluskey P, Lightman S. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology. 2005;112(11):1916.e1-7.
14. Androudi S, Letko E, Meniconi M, Papadaki T, Ahmed M, Foster CS. Safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema. Ocul Immunol Inflamm. 2005;13(2-3):205-212.
15. Sallam A, Comer RM, Chang JH, et al. Short-term safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema in children. Arch Ophthalmol. 2008;126(2):200-205.
16. Young S, Larkin G, Branley M, Lightman S. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Experiment Ophthalmol. 2001;29(1):2-6.
17. Galor A, Margolis R, Brasil OM, et al. Adverse events after intravitreal triamcinolone in patients with and without uveitis. Ophthalmology. 2007;114(10):1912-1918.
18. Lardenoye CW, van Kooij B, Rothova A. Impact of macular edema on visual acuity in uveitis. Ophthalmology. 2006;113(8):1446-1449.
19. Rothova A. Inflammatory cystoid macular edema. Curr Opin Ophthalmol. 2007;18(6):487-492.
20. Fine HF, Baffi J, Reed GF, Csaky KG, Nussenblatt RB. Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema. Am J Ophthalmol. 2001;132(5):794-796.